Introduction {#s1}
============

SLE is a chronic systemic autoimmune disorder characterised by a disruptive innate and adaptive immunity requiring immunomodulatory and immunosuppressive therapies. Hydroxychloroquine (HCQ), an antimalarial drug with immunomodulatory properties, remains one of the most important drugs in SLE. Multiple studies have demonstrated its favourable effects in SLE, such as reducing disease exacerbations, damage accrual and mortality.[@R1] Despite its several therapeutic benefits, HCQ-induced retinal toxicity remains a major concern. This adverse event is reported to be below 1% during the first 5 years of drug treatment, but increases to 2% during the next 5 years and up to 20% after 20 years of therapy.[@R3] For this reason, the American Academy of Ophthalmology (AAO) recommended guidelines regarding the screening and risks of retinal toxicity. Previously, the AAO recommended HCQ dose ≤6.5 mg/kg/day (ideal body weight) to reduce the risk of retinal toxicity, but in the revised guidelines of 2016 the safety dose was changed to ≤5 mg/kg/day (actual body weight).[@R3] However, it is unclear if this change in HCQ dose has a significant impact on the short-term and long-term outcomes of patients with SLE and whether or not this dose reduction would be effective in controlling the disease. Therefore, we examined the effect of HCQ dose adjustment to ≤5 mg/kg/day on the clinical outcomes of a cohort of Puerto Ricans with SLE.

Methods {#s2}
=======

Study population {#s2-1}
----------------

A retrospective study was performed in a cohort of patients with SLE followed from July 1992 to March 2020 at the rheumatology clinic of the University of Puerto Rico Medical Sciences Campus and a private rheumatology practice located in San Juan, Puerto Rico. Patients with SLE whose HCQ dose was adjusted to ≤5 mg/kg/day of actual body weight were studied. All patients fulfilled the revised 1997 American College of Rheumatology (ACR) classification criteria for SLE,[@R4] were ≥21 years of age, had Puerto Rican ethnicity (self and four grandparents), received HCQ treatment (at stable dose) for at least 2 years prior to dose adjustment, and had 2 years of follow-up after dose adjustment. Those who developed HCQ-induced retinopathy and who discontinued HCQ were excluded. Baseline visit was defined as that where HCQ dose was adjusted to ≤5 mg/kg/day. HCQ dose adjustments were started in 2016 after publication of the AAO guidelines. Study visits were ascertained every 6 months for 2 years prior to and for 2 years after HCQ dose adjustment. A waiver for written informed consent was received.

Baseline variables {#s2-2}
------------------

At baseline visit, information including demographic parameters (sex, age, SLE disease duration), cumulative (at any time until baseline visit) SLE manifestations (per ACR criteria), serological tests, disease activity, disease damage, selected comorbidities and pharmacological treatment was determined. Disease activity was assessed using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and disease damage by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI).[@R5] Comorbidities included tobacco use, overweight/obesity (body mass index ≥25), arterial hypertension, diabetes mellitus, dyslipidaemia, coronary artery disease, hypothyroidism, chronic kidney disease, cataracts and diabetic retinopathy. Current (within 1 month of baseline visit) and cumulative (at any time until baseline visit) SLE pharmacotherapy (corticosteroids, mycophenolate mofetil, azathioprine, cyclophosphamide, tacrolimus, methotrexate, rituximab and non-steroidal anti-inflammatory drugs) were gathered.

Clinical outcomes {#s2-3}
-----------------

Disease activity (per SLEDAI), SLE exacerbations, hospitalisations (any cause and hospitalisations attributed to SLE), emergency room visits (any cause and emergency room visits attributed to SLE), damage accrual (per SDI), prednisone (or equivalent) exposure and dose, and exposure to other immunosuppressive drugs were determined before and after baseline visits. SLE exacerbation was defined as an increase in disease activity requiring an adjustment of immunosuppressive therapy.[@R7] Finally, mortality, if any, was assessed at these study periods.

Patient and public involvement {#s2-4}
------------------------------

Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research.

Statistical analyses {#s2-5}
--------------------

SLEDAI scores, SLE exacerbations, emergency room visits, hospitalisations, SDI score, prednisone (or equivalent) exposure, prednisone (or equivalent) mean dose and exposure to other immunosuppressive drugs were compared before and after HCQ dose adjustment. The mean number of exacerbations, emergency room visits and hospitalisations for each 6-month study period, before and after HCQ adjustment, was calculated. Visits before (24, 18, 12 and 6 months prior to baseline) and after (6, 12, 18 and 24 months after baseline) HCQ dose adjustment were grouped to make these comparisons. Furthermore, line graphs were used to display trends in prednisone dose, SLEDAI score and SDI score data. Statistical analyses were performed using exact McNemar's test and Wilcoxon signed-rank test, as appropriate. Statistical significance was set at p\<0.05. Statistical analysis was performed using STATA V.15.

Results {#s3}
=======

The entire cohort of patients with SLE consisted of 412 patients. Sixty (15%) patients fulfilled the study criteria and were included in the analyses. The mean age (SD) of the study population was 43.8 (15.1) years, and all patients were women. The mean (SD) SLE duration was 13.8 (9.1) years and the mean (SD) HCQ treatment duration was 12.5 (15.1) years. At baseline, the mean (SD) height was 1.58 (0.07) m and weight was 58.4 (10.1) kg. The mean (SD) HCQ doses before and after adjustment were 398.3 (12.8) mg/day and 246.7 (49.9) mg/day, respectively. The mean (SD) HCQ dose/kg before and after adjustment were 6.8 (1.2) mg/kg and 4.2 (0.9) mg/kg, respectively. No deaths occurred during the study period. [Table 1](#T1){ref-type="table"} shows the demographic characteristics, SLE manifestations, serological tests, SLEDAI score, SDI score, comorbid conditions and pharmacological therapy at baseline visit.

###### 

Baseline demographic characteristics, SLE manifestations, serological tests, disease activity, disease damage, comorbid conditions and pharmacological therapy

  Characteristics                                      
  -------------------------------------- ------------- ------------
  Sex, % female                          100           
  Age, mean (SD)                         43.8 (15.1)   
  SLE duration, mean years (SD)          13.8 (9.1)    
  Cumulative ACR criteria, %                           
   Malar rash                            51.7          
   Discoid rash                          8.3           
   Photosensitivity                      61.7          
   Oral ulcers                           35.0          
   Non-scarring alopecia                 28.8          
   Arthritis                             80.0          
   Pericarditis                          11.7          
   Pleuritis                             13.3          
   Cellular casts                        16.7          
   Proteinuria                           40.0          
   Seizures                              10.0          
   Psychosis                             3.3           
   Haemolytic anaemia                    3.3           
   Leucopenia (\<4.0 x 10^9^/L)          61.7          
   Lymphopaenia (\<1.5 x 10^9^/L)        86.7          
   Thrombocytopaenia (\<100 x 10^9^/L)   8.3           
   ANA                                   95.0          
   Anti-dsDNA antibodies                 71.7          
   Anti-Smith antibodies                 20.0          
   Anticardiolipin antibodies            23.3          
   Lupus anticoagulant test              13.3          
  Other serological tests, %                           
   Anti-Ro antibodies                    33.3          
   Anti-La antibodies                    11.7          
   Low C3                                72.9          
   Low C4                                66.1          
  SLEDAI                                               
   Mean score (SD)                       1.75 (3.1)    
   Median score (P25--P75)               0 (0--2)      
  SDI                                                  
   Mean score (SD)                       0.91 (1.4)    
   Median score (P25--P75)               0 (0--1.5)    
  Comorbidities, %                                     
   Tobacco use                           6.7           
   Overweight/obesity                    20.0          
   Arterial hypertension                 50.0          
   Diabetes mellitus                     3.3           
   Dyslipidaemia                         41.7          
   Coronary artery disease               1.7           
   Hypothyroidism                        20.0          
   Chronic kidney disease                3.3           
   Cataracts                             11.7          
   Diabetic retinopathy                  0.0           
  SLE treatment, %                       Current       Cumulative
   Corticosteroids                       56.7          98.3
   Mycophenolate mofetil                 28.3          38.3
   Azathioprine                          5.1           33.3
   Cyclophosphamide                      0.0           20.0
   Tacrolimus                            3.3           6.7
   Methotrexate                          1.7           11.7
   Rituximab                             0.0           3.3
   NSAIDs                                10.2          50.0

ACR, American College of Rheumatology; Anti-dsDNA, anti-double stranded DNA; NSAIDs, non-steroidal anti-inflammatory drugs; P, percentile; SDI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.

[Table 2](#T2){ref-type="table"} depicts the outcome measures before and after HCQ dose adjustment. Patients required a lower mean prednisone (or equivalent) daily dose (7.9±17.4 mg vs 4.8±5.1 mg, p=0.047) when compared with visits prior to HCQ dose reduction. No significant differences were observed regarding mean SLEDAI scores, lupus exacerbations, emergency room visits (any cause), emergency room visits attributed to SLE, mean hospitalisations (any cause), mean hospitalisations attributed to SLE and mean SDI before and after HCQ dose adjustment. Also, no differences were observed for exposure to corticosteroids, mycophenolate mofetil, azathioprine, cyclophosphamide, tacrolimus, rituximab or methotrexate. Furthermore, no significant differences were found for patients using prednisone higher than 5 and 7.5 mg daily (at any moment) before and after HCQ dose change. [Figure 1A, B and C](#F1){ref-type="fig"} show the mean prednisone daily dose, SLEDAI scores and SDI scores, respectively, for each visit before and after HCQ dose adjustment. Compared with baseline visit, no significant differences were observed for SLEDAI scores or SDI scores for each study visit before and after HCQ change.

![Means (±SE) of (A) prednisone dose (mg/day), (B) Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores and (C) Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) scores for each study visit before and after HCQ dose adjustment are shown. HCQ, hydroxychloroquine.](lupus-2020-000395f01){#F1}

###### 

Clinical outcomes and pharmacological therapy before and after HCQ dose adjustment

  Parameters                                  Visits prior to adjustment   Visits after adjustment   P value
  ------------------------------------------- ---------------------------- ------------------------- ---------
  Outcome measures                                                                                   
  SLEDAI                                                                                             
   Mean score (SD)                            2.2 (2.9)                    2.1 (3.0)                 0.958
   Median score (P25--P75)                    1 (0--3)                     1 (0--3.1)                
  SLE exacerbations                                                                                  
   Mean (SD)                                  0.18 (0.25)                  0.13 (0.21)               0.256
   Median (P25--P75)                          0 (0--0.25)                  0 (0--0.25)               
  Total emergency room visits, mean (SD)                                                             
   Mean (SD)                                  0.06 (0.22)                  0.01 (0.05)               0.284
   Median (P25--P75)                          0 (0--0)                     0 (0--0)                  
  Emergency room visits attributed to SLE                                                            
   Mean (SD)                                  0.02 (0.08)                  0.00 (0.03)               0.313
   Median (P25--P75)                          0 (0--0)                     0 (0--0)                  
  Total hospitalisations                                                                             
   Mean (SD)                                  0.08 (0.19)                  0.04 (0.10)               0.322
   Median (P25--P75)                          0 (0--0)                     0 (0--0)                  
  Hospitalisations attributed to SLE                                                                 
   Mean (SD)                                  0.04 (0.16)                  0.00 (0.03)               0.083
   Median (P25--P75)                          0 (0--0)                     0 (0--0)                  
  SDI                                                                                                
   Mean score (SD)                            0.84 (1.28)                  0.98 (1.42)               0.076
   Median score (P25--P75)                    0 (0--1)                     0 (0--1.5)                
  Pharmacological therapy                                                                            
  Corticosteroids, %                          68.3                         65.0                      0.727
  Prednisone (or equivalent)                                                                         
  Mean mg/day (SD)                            7.9 (17.4)                   4.8 (5.1)                 0.047
  Median mg/day (P25--P75)                    5 (0--9.8)                   5 (0--7.7)                
  Prednisone \>5 mg daily at any point, %     48.3                         40.0                      0.230
  Prednisone \>7.5 mg daily at any point, %   45.0                         35.0                      0.150
  Mycophenolate, %                            28.3                         30.0                      \>0.99
  Azathioprine, %                             10.0                         8.3                       \>0.99
  Cyclophosphamide, %                         1.7                          1.7                       \>0.99
  Tacrolimus, %                               1.7                          6.7                       0.250
  Methotrexate, %                             3.3                          5.0                       \>0.99
  Rituximab, %                                0.0                          0.0                       \>0.99
  NSAIDs, %                                   15.0                         18.3                      0.688

Exact McNemar's test or Wilcoxon signed-rank test was used for statistical analyses.

HCQ, hydroxychloroquine; NSAIDs, non-steroidal anti-inflammatory drugs; P, percentile; SDI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.

We further stratified patients according to HCQ dose adjustment. Thirty-one patients had a dose reduction of 200 mg daily and 29 patients had a dose reduction of 100 mg daily. For each group of patients, no differences were observed before and after HCQ dose adjustments with regard to SLEDAI scores, lupus exacerbations, emergency room visits, hospitalisations, SDI scores and exposure to immunosuppressive drugs (data not shown).

Discussion {#s4}
==========

We examined the clinical outcomes in a group of patients with SLE from Puerto Rico whose HCQ dose was decreased to ≤5 mg/kg/day (actual body weight) according to the 2016 AAO guidelines regarding HCQ-induced retinopathy. We did not observe significant differences in disease activity, SLE exacerbations, emergency room visits, hospitalisations, damage accrual, and exposure to corticosteroids or other immunosuppressive therapies before and 2 years after HCQ dose change. The mean prednisone daily dose was lower after HCQ dose adjustment. Thus, our findings suggest that adjusting HCQ dose per the AAO recommendations does not have a significant impact on the clinical outcomes of patients with SLE.

Few data exist regarding the therapeutic concentrations at which HCQ exerts its immunomodulatory properties at the cellular level. The effect of HCQ dosing in the modulation of inflammatory cytokines has not been extensively studied. HCQ exerts its immunomodulatory effect by downregulating Toll-like receptors (TLRs) 3, 7 and 9 in plasmacytoid dendritic cells. These are the major producers of interferon-α (IFN-α), which is known to have a major role in the pathogenesis of SLE.[@R8] In a group of patients with SLE from LUMINA, Willis *et al*[@R8] found that treatment with HCQ was associated with reduced levels of tumour necrosis factor-α (TNF-α) and IFN-α compared with patients with SLE not receiving HCQ, and that the reduction in IFN-α levels strongly correlated with lower disease activity. Noteworthy, Sacre *et al*[@R9] found no significant differences in IFN-α and TNF-α production by plasmacytoid dendritic cells on in vitro stimulation of TLR-7 and TLR-9 between subjects receiving 400 mg/daily and 200 mg/daily of HCQ. These findings suggest that proinflammatory cytokine inhibition by HCQ may be achieved with lower doses of the drug.

HCQ has a distinctive pharmacokinetic profile. Its bioavailability has been reported to be approximately 70% with an extensive tissue distribution. HCQ has a long elimination half-life of nearly 40 days and steady-state levels are achieved after 6 months of therapy.[@R10] As a result, the relationship between dosing, therapeutic blood concentration and its correlation with SLE disease activity remains uncertain. Durcan *et al*[@R11] observed an association between lower HCQ blood concentrations and higher disease activity in patients with SLE. Likewise, Costedoat-Chalumeau *et al*[@R12] found that low HCQ concentration was a predictor of SLE exacerbations and higher disease activity, and proposed a therapeutic level whole blood concentration of 1000 ng/mL. However, in the PLUS study the same authors found that adapting HCQ dose to achieve HCQ concentration levels \>1000 ng/mL did not reduce SLE flares over a 7-month follow-up period.[@R13]

Few studies have examined the clinical effect of lowering HCQ dose in patients with SLE. Grossman *et al*[@R14] studied a population of patients with SLE who received different body weight-based doses of \<4 mg/kg/day, 4--4.99 mg/kg/day, 5--5.99 mg/kg/day and ≥6 mg/kg/day and found no differences in disease activity among the different dosing groups. They also noted no differences in disease exacerbations using the Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)-SLEDAI flare instrument and no significant changes in patients' global assessment.[@R14] These findings are in line with those reported in our study.

Some limitations of our study must be highlighted. First, the study population was small. Also, we did not make comparisons with patients who did not require HCQ adjustment, particularly with those who were near the cut-off as the latter group of patients was very small. Nonetheless, we considered the natural course of SLE characterised by fluctuations in disease expression and analysed trends in outcome variables for 2 years before HCQ adjustment; thus, we could better compare with the disease course after dose adjustment. Second, this study was performed in a group of Puerto Rican patients who may not be representative of other ethnic groups. Third, no male patients were included as none of those participating in the entire cohort required dose adjustment. Fourth, we did not gather data concerning adherence to immunosuppressive drugs, including HCQ. Nevertheless, adequate adherence may be inferred by the low levels of SLE disease activity observed in our study population, both before and after HCQ dose adjustment. Finally, the follow-up period of 2 years was relatively short to determine the impact of HCQ dose adjustment on the long-term outcomes. The Canadian Hydroxychloroquine Study Group studied the long-term effect of HCQ withdrawal in patients with SLE with stable disease and found that during 3 years of follow-up 50% of patients who discontinued HCQ experienced a major flare of their disease compared with 28% of those who continued treatment.[@R15] The mean time to major SLE exacerbation was 29.4 months after drug withdrawal. This study suggests that the protective effects of HCQ remain for a long period of time, possibly longer if the drug dose is lowered rather than discontinued such as in our research work.

In conclusion, this study suggests that the adjustment of HCQ daily dose to ≤5 mg/kg/day of actual body weight does not have a significant impact on the short-term and mid-term outcomes of patients with SLE. Nevertheless, further studies including a larger number of patients and longer follow-up are necessary to reach further conclusions.
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